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October 2015 and retrospectively analysed, providing 141 
dose measurements for all the MOSkins. Measured and 
calculated contributions by each single catheter were 
quantified separately. Discrepancies were plotted depending 
on weighted average polar angles and distances between 
MOSkins and source, and a linearly fitting CF was calculated. 
 
Results: A correction function CF linearly depending on the 
weighted average distance and polar angle of the catheter 
from the dosimeter was obtained (R=0.35, showing a 
significant correlation). The results showed an increase in 
sensitivity of MOSkins at higher distances (i.e., due to 
radiation softening) and at wider polar angles (i.e., due to 
increased radiation contamination by the presence of the 
TRUS probe). The percentage dose discrepancy between 
calculated and measured dose contribution from each single 
catheter with and without the application of obtained CF 





Conclusion: The use of the CF significantly reduces 
percentage discrepancy between planned and measured dose 
per single catheter. Implementation of the CF to correct 
MOSkin readings online is a further step towards accurate and 
reliable real time IVD in prostate BT performed with the DPP. 
Based on the real time measured dose discrepancy, the next 
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Purpose or Objective: Rotating shield brachytherapy (RSBT) 
is an intensity modulated high dose rate (HDR) BT treatment 
technique, where radiation sources are surrounded by 
catheters containing rotating shields that direct radiation 
towards the tumour and away from healthy tissues. RSBT for 
HDR requires sources with lower energies than Ir-192, such as 
Gd-153 and Se-75, due to shield thickness constraints. The 
distinct features of shield angle, catheter material and 
source isotope require the development of a specific Monte 
Carlo (MC)-based treatment planning and optimization 
system. 
 
Material and Methods: An MC based dose calculation engine 
for RSBT has been developed and coupled with a column-
generation optimizer. At every iteration of the optimization 
loop, the column-generation process solves a pricing problem 
to determine the best dwell position and shield angle 
combination to add to the treatment plan, resulting in the 
best possible plan with the shortest treatment time. 
As a source model, the microSelectron-v2 source geometry 
was selected and placed inside a cylindrical platinum shield 
with a diameter of 1.8 mm and 3.0 mm for interstitial and 
intracavitary cases, respectively. An emission window 
coinciding with the active core of the source was created by 
removing half (180º) of the wall of the shield. 
For an interstitial prostate case, RSBT plans were generated 
only using Gd-153 as a source due to the extreme limitations 
on shield size in interstitial catheters. For the intracavitary 
GYN case, both Gd-153 and Se-75 plans were generated. All 
RSBT plans were compared with conventional HDR BT. Only 
the original dwell positions used in conventional BT were 
sampled to create the RSBT plans. 
 
Results: RSBT plans resulted in a considerable reduction in 
both rectum and bladder doses without sacrificing target 
coverage for the prostate case. With 95% of the PTV volume 
receiving over 15 Gy, only 40% of the rectum volume received 
more than 2 Gy for the Gd-153 RSBT case,as opposed to 85% 
for the unshielded Ir-192 conventional plan. 
 
 
For the GYN patient, the median rectum dose was 2.4 Gy, 3.2 
Gy and 3.45 Gy for Gd-153 RSBT, Se-75 RSBT and unshielded 
Ir-192, respectively, with an identical target coverage. The 
Gd-153 case was also able to reduce the dose to the bladder 
by 41%. 
 
Conclusion: The development of the first MC-based TPS 
devoted to RSBT has been successfully accomplished. For the 
prostate case, a significant dosimetric improvement was 
achieved over conventional BT using Gd-153 with optimized 
shield angles. For the GYN case, the improvement was 
diminished by the central position of the conventional BT 
dwell positions within the target volume. RSBT allows the 
placement of dwell positions much closer to normal tissue, 
which will yield superior dose distributions when properly 
optimized. RSBT will decrease normal tissue toxicity and 
allow for tailoring treatments to each individual patient by 
treating all parts of the tumour without over-irradiation of 
large regions of normal tissues. 
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Purpose or Objective: Acute dysphagia is a frequently 
observed toxicity during concurrent chemo-radiation (CRT) or 
high-dose radiotherapy (RT) for lung cancer. This toxicity can 
lead to hospitalizations, treatment interruptions and 
